

## **Ordinary and Extraordinary General Meeting of April 20, 2020**

### **Company provides details on the ability to give a proxy**

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today provided further proxy details about its General Meeting to be held on April 20, 2020, in addition to the information contained in its notice of meeting and its press releases published on April 3, 2020 and April 10, 2020, respectively.

In accordance with Article 6 of the French Decree no. 2020-418 of April 10, 2020, in the event that a shareholder gives a proxy to a designated person, proxy forms with an indication of the proxy holder (including those given via Votaccess) may validly be received by the Company until the fourth day prior to the date of the General Meeting. The proxy holder may send the Company his/her instructions for the exercise of the proxy to: [investors@dbv-technologies.com](mailto:investors@dbv-technologies.com), no later than the fourth day prior to the date of the General Meeting.

As an exception to Section III of Article R. 225-85 of the French Commercial Code, a shareholder who has already either 1) expressed his or her vote by mail, 2) sent a proxy or 3) requested an admission card or a certificate of participation, may choose another means of participation in the General Meeting provided that his or her instruction to this effect reaches the company within the time required for the new mode of participation chosen. The previous instructions received will then be cancelled.

The General Meeting will be chaired by Mr. Michel de Rosen, Chairman of the Board of Directors, and can be accessed at: <https://www.dbv-technologies.com> in the Events and Presentations section.

### **About DBV Technologies**

DBV Technologies is developing Viaskin®, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical trial of Viaskin Milk for the treatment of Eosinophilic



Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Company's ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company's ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

#### **DBV Investor Relations Contact**

Sara Blum Sherman  
Senior Director, Investor Relations & Strategy  
+1 212-271-0740  
[sara.sherman@dbv-technologies.com](mailto:sara.sherman@dbv-technologies.com)

#### **DBV Media Contact**

Joe Becker  
VP, Global Corporate Communications  
+1 646-650-3912  
[joseph.becker@dbv-technologies.com](mailto:joseph.becker@dbv-technologies.com)